CalciMedica, Inc. Common Stock
$1.92
-$0.05 (-2.54%)
$1.92Day Range$2.00
Key Statistics
Market Cap
$13.11M
Shares Outstanding
6.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 25, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$1.98
Day High
$2.00
Day Low
$1.92
Volume
60.2K
VWAP
$1.94
Prev Close
$1.97
Transactions
--
Acc. Volume
--
About CalciMedica, Inc. Common Stock
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
PHARMACEUTICAL PREPARATIONSSIC 283415 employees505 COAST BOULEVARD SOUTH, LA JOLLA, CA, 92037858-952-5500IPO Sep 25, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001534133
- Composite FIGI
- BBG0088HHJ97
- Share Class FIGI
- BBG0088HHJB4
- Ticker Root
- CALC
- SIC Code
- 2834
About CalciMedica, Inc. Common Stock (CALC) Stock
CalciMedica, Inc. Common Stock (CALC) closed the 2026-09-18 session at $1.92, down 2.54% versus the previous close (-0.05). The stock opened at $1.98 and traded between $1.92 and $2.00 during that session. Session trading volume was 60K shares. The volume-weighted average price (VWAP) is $1.94.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
CalciMedica, Inc. Common Stock has a market capitalization of $13.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. CALC is listed on the XNAS exchange. The company employs approximately 15 people. CalciMedica, Inc. Common Stock is headquartered in LA JOLLA, CA. The recorded listing date is 2020-09-25.
On this page you can find market CALC stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.